Renal cell carcinoma is highly resistant to systemic chemotherapy, and no agent should be considered standard in the treatment of metastatic disease. At this time, it is appropriate for patients with advanced local or metastatic renal cell carcinoma to be offered new therapeutic investigational experimental options, since clearly there are limited therapies presently available. The experience with chemotherapy is reviewed.